Acknowledgement
This study has received funding by the Fundamental Research Program of Shanxi Province (No. 202203021212062 and 202103021222014), the National Natural Science Foundation of China (No. 82171923 and 82371952), the Central Government Guided Local Science and Technology Development Fund Project (No. YDZJSX20231B012), the Project of Shanxi Provincial Health Commission (No. 2021XM51 and 2023XM014), and the National Cancer Regional Medical Center Science and Education Cultivation Fund (No. BD2023003 and SD2023001).
References
- Higgins T, Mittendorf EA. Peritumoral lidocaine injection: a low-cost, easily implemented intervention to improve outcomes in early-stage breast cancer. J Clin Oncol 2023;41:3287-3290
- Boughey JC, Ballman KV, Hunt KK, McCall LM, Mittendorf EA, Ahrendt GM, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 trial (Alliance). J Clin Oncol 2015;33:3386-3393
- Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569-575
- Lim GH, Upadhyaya VS, Acosta HA, Lim JMA, Allen JC Jr, Leong LCH. Preoperative predictors of high and low axillary nodal burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result. Eur J Surg Oncol 2018;44:945-950
- Kim WH, Kim HJ, Lee SM, Cho SH, Shin KM, Lee SY, et al. Prediction of high nodal burden with ultrasound and magnetic resonance imaging in clinically node-negative breast cancer patients. Cancer Imaging 2019;19:4
- Lim GH, Teo SY, Allen JC Jr, Chinthala JP, Leong LCH. Determining whether high nodal burden in early breast cancer patients can be predicted preoperatively to avoid sentinel lymph node biopsy. J Breast Cancer 2019;22:67-76
- Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol 2017;3:549-555
- Chang JM, Leung JWT, Moy L, Ha SM, Moon WK. Axillary nodal evaluation in breast cancer: state of the art. Radiology 2020;295:500-515
- Kuijs VJ, Moossdorff M, Schipper RJ, Beets-Tan RG, Heuts EM, Keymeulen KB, et al. The role of MRI in axillary lymph node imaging in breast cancer patients: a systematic review. Insights Imaging 2015;6:203-215
- Yi CB, Ding ZY, Deng J, Ye XH, Chen L, Zong M, et al. Combining the ultrasound features of primary tumor and axillary lymph nodes can reduce false-negative rate during the prediction of high axillary node burden in BI-RADS category 4 or 5 breast cancer lesions. Ultrasound Med Biol 2020;46:1941-1948
- Li JW, Tong YY, Jiang YZ, Shui XJ, Shi ZT, Chang C. Clinicopathologic and ultrasound variables associated with a heavy axillary nodal tumor burden in invasive breast carcinoma. J Ultrasound Med 2019;38:1747-1755
- Dihge L, Bendahl PO, Ryden L. Nomograms for preoperative prediction of axillary nodal status in breast cancer. Br J Surg 2017;104:1494-1505
- Zhao F, Cai C, Liu M, Xiao J. Identification of the lymph node metastasis-related automated breast volume scanning features for predicting axillary lymph node tumor burden of invasive breast cancer via a clinical prediction model. Front Endocrinol (Lausanne) 2022;13:881761
- Mann RM, Cho N, Moy L. Breast MRI: state of the art. Radiology 2019;292:520-536
- Xu Z, Ding Y, Zhao K, Han C, Shi Z, Cui Y, et al. MRI characteristics of breast edema for assessing axillary lymph node burden in early-stage breast cancer: a retrospective bicentric study. Eur Radiol 2022;32:8213-8225
- Li J, Ma W, Jiang X, Cui C, Wang H, Chen J, et al. Development and validation of nomograms predictive of axillary nodal status to guide surgical decision-making in early-stage breast cancer. J Cancer 2019;10:1263-1274
- Cheon H, Kim HJ, Lee SM, Cho SH, Shin KM, Kim GC, et al. Preoperative MRI features associated with lymphovascular invasion in node-negative invasive breast cancer: a propensity-matched analysis. J Magn Reson Imaging 2017;46:1037-1044
- Zhang S, Zhang D, Yi S, Gong M, Lu C, Cai Y, et al. The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis. Oncotarget 2017;8:2863-2873
- D'Orsi CJ, Sickles EA, Mendelson EB, Morris EA. ACR BI-RADS atlas: breast imaging reporting and data system. 5th ed. Reston: American College of Radiology, 2013
- Byon JH, Park YV, Yoon JH, Moon HJ, Kim EK, Kim MJ, et al. Added value of MRI for invasive breast cancer including the entire axilla for evaluation of high-level or advanced axillary lymph node metastasis in the post-ACOSOG Z0011 trial era. Radiology 2021;300:46-54
- Harada TL, Uematsu T, Nakashima K, Sugino T, Nishimura S, Takahashi K, et al. Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer? Eur Radiol 2020;30:3363-3370
- Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, et al. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 2021;185:1-12
- Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 2018;36:2105-2122
- Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013;24:2206-2223
- Park SH, Han K, Park SY. Mistakes to avoid for accurate and transparent reporting of survival analysis in imaging research. Korean J Radiol 2021;22:1587-1593
- Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-7259
- Cheon H, Kim HJ, Kim TH, Ryeom HK, Lee J, Kim GC, et al. Invasive breast cancer: prognostic value of peritumoral edema identified at preoperative MR imaging. Radiology 2018;287:68-75
- Kwon BR, Shin SU, Kim SY, Choi Y, Cho N, Kim SM, et al. Microcalcifications and peritumoral edema predict survival outcome in luminal breast cancer treated with neoadjuvant chemotherapy. Radiology 2022;304:310-319
- Baltzer PA, Yang F, Dietzel M, Herzog A, Simon A, Vag T, et al. Sensitivity and specificity of unilateral edema on T2w-TSE sequences in MR-mammography considering 974 histologically verified lesions. Breast J 2010;16:233-239
- Koyama H, Kobayashi N, Harada M, Takeoka M, Kawai Y, Sano K, et al. Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment. Am J Pathol 2008;172:179-193
- Song SE, Park EK, Cho KR, Seo BK, Woo OH, Jung SP, et al. Additional value of diffusion-weighted imaging to evaluate multifocal and multicentric breast cancer detected using pre-operative breast MRI. Eur Radiol 2017;27:4819-4827
- Grimm LJ, Johnson KS, Marcom PK, Baker JA, Soo MS. Can breast cancer molecular subtype help to select patients for preoperative MR imaging? Radiology 2015;274:352-358
- Weissenbacher TM, Zschage M, Janni W, Jeschke U, Dimpfl T, Mayr D, et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat 2010;122:27-34
- Fushimi A, Yoshida A, Yagata H, Takahashi O, Hayashi N, Suzuki K, et al. Prognostic impact of multifocal and multicentric breast cancer versus unifocal breast cancer. Surg Today 2019;49:224-230
- Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol 2018;25:1783-1785
- Bitencourt AGV, Eugenio DSG, Souza JA, Souza JO, Makdissi FBA, Marques EF, et al. Prognostic significance of preoperative MRI findings in young patients with breast cancer. Sci Rep 2019;9:3106